Differential Sensitivities of Bladder Cancer Cell Lines to Resveratol Are Unrelated to Its Metabolic Profile

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Feb 9

PMID 28178690

Citations 10

Authors

Yang Yang

Chuangang Li

Hong Li

Moli Wu

Changle Ren

Yuhong Zhen

Xiaochi Ma

Yunpeng Diao

Xiaodong Ma

Sa Deng

Jia Liu

Xiaohong Shu

Affiliations

Soon will be listed here.

Abstract

Resveratrol (RV) is a natural polyphenol compound with a wide range of activities, including inhibition of human bladder cancer (HBC) cell growth. Because RV is rapidly metabolized and has poor bioavailability, it is unclear whether the antitumor activity is due to RV or its metabolites. We therefore used liquid chromatography-mass spectroscopy, qRT-PCR, immunocytochemistry and western blotting to evaluate the metabolic profile and biotransformation of RV in the T24 and EJ HBC cell lines. Both T24 and EJ cells generated the same RV metabolite, RV monosulfate (RVS), and both exhibited upregulation of the RV-associated metabolic enzyme SULT1A1 (sulfotransferase). Despite these similarities, T24 cells were more sensitive to RV than EJ cells, yet T24 cells exhibited no sensitivity to an RVS mixture (84.13% RVS). Primary rat bladder epithelial cells showed no adverse effects when exposed to a therapeutic dose (100 μM) of RV. The differences in RV sensitivity between the two HBC cell lines did not reflect differences in the RV metabolic profile or SULT1A1 expression. Because RV exhibited stronger antitumor activity and better safety than RVS, we conclude that RV has significant therapeutic potential for HBC treatment, provided individual differences are considered during clinical research and application.

Citing Articles

Focus on the Use of Resveratrol in Bladder Cancer.

Zucchi A, Claps F, Pastore A, Perotti A, Biagini A, Sallicandro L Int J Mol Sci. 2023; 24(5).

PMID: 36901993 PMC: 10003096. DOI: 10.3390/ijms24054562.

Micelle/Hydrogel Composite as a "Natural Self-Emulsifying Reversible Hybrid Hydrogel (N'SERH)" Enhances the Oral Bioavailability of Free (Unconjugated) Resveratrol.

Joseph A, Balakrishnan A, Shanmughan P, Maliakel B, Madhavamenon K ACS Omega. 2022; 7(15):12835-12845.

PMID: 35474815 PMC: 9026114. DOI: 10.1021/acsomega.2c00116.

The Green Anti-Cancer Weapon. The Role of Natural Compounds in Bladder Cancer Treatment.

Wigner P, Bijak M, Saluk-Bijak J Int J Mol Sci. 2021; 22(15).

PMID: 34360552 PMC: 8346071. DOI: 10.3390/ijms22157787.

A Brief Updated Review of Advances to Enhance Resveratrol's Bioavailability.

de Vries K, Strydom M, Steenkamp V Molecules. 2021; 26(14).

PMID: 34299642 PMC: 8305180. DOI: 10.3390/molecules26144367.

Resveratrol effects in bladder cancer: A mini review.

Almeida T, Silva G Genet Mol Biol. 2021; 44(1):e20200371.

PMID: 33749701 PMC: 7983189. DOI: 10.1590/1678-4685-GMB-2020-0371.

References

Hung R, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F . GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 2004; 110(4):598-604. DOI: 10.1002/ijc.20157. View

Lin X, Wu G, Huo W, Zhang Y, Jin F . Resveratrol induces apoptosis associated with mitochondrial dysfunction in bladder carcinoma cells. Int J Urol. 2012; 19(8):757-64. DOI: 10.1111/j.1442-2042.2012.03024.x. View

Howitz K, Bitterman K, Cohen H, Lamming D, Lavu S, Wood J . Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003; 425(6954):191-6. DOI: 10.1038/nature01960. View

Shu X, Wang L, Li H, Song X, Shi S, Gu J . Diffusion Efficiency and Bioavailability of Resveratrol Administered to Rat Brain by Different Routes: Therapeutic Implications. Neurotherapeutics. 2015; 12(2):491-501. PMC: 4404447. DOI: 10.1007/s13311-014-0334-6. View

Mercolini L, Saracino M, Bugamelli F, Ferranti A, Malaguti M, Hrelia S . HPLC-F analysis of melatonin and resveratrol isomers in wine using an SPE procedure. J Sep Sci. 2008; 31(6-7):1007-14. DOI: 10.1002/jssc.200700458. View

Strange R, Fryer A . The glutathione S-transferases: influence of polymorphism on cancer susceptibility. IARC Sci Publ. 1999; (148):231-49. View

Allali-Hassani A, Pan P, Dombrovski L, Najmanovich R, Tempel W, Dong A . Structural and chemical profiling of the human cytosolic sulfotransferases. PLoS Biol. 2007; 5(5):e97. PMC: 1847840. DOI: 10.1371/journal.pbio.0050097. View

Qian G, Leung S, Lu G, Leung K . Optimization and validation of a chromatographic method for the simultaneous quantification of six bioactive compounds in Rhizoma et Radix Polygoni Cuspidati. J Pharm Pharmacol. 2007; 60(1):107-13. DOI: 10.1211/jpp.60.1.0014. View

Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat B, Fernandez-Salguero P . The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol. 2002; 64(9):1375-86. DOI: 10.1016/s0006-2952(02)01296-0. View

10.

Aires V, Limagne E, Cotte A, Latruffe N, Ghiringhelli F, Delmas D . Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Mol Nutr Food Res. 2013; 57(7):1170-81. DOI: 10.1002/mnfr.201200766. View

11.

Potter G, Patterson L, Wanogho E, Perry P, Butler P, Ijaz T . The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer. 2002; 86(5):774-8. PMC: 2375304. DOI: 10.1038/sj.bjc.6600197. View

12.

Zhou R, Fukui M, Choi H, Zhu B . Induction of a reversible, non-cytotoxic S-phase delay by resveratrol: implications for a mechanism of lifespan prolongation and cancer protection. Br J Pharmacol. 2009; 158(2):462-74. PMC: 2757685. DOI: 10.1111/j.1476-5381.2009.00268.x. View

13.

Brown V, Patel K, Viskaduraki M, Crowell J, Perloff M, Booth T . Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010; 70(22):9003-11. PMC: 2982884. DOI: 10.1158/0008-5472.CAN-10-2364. View

14.

Lotan Y, Amiel G, Boorjian S, Clark P, Droller M, Gingrich J . Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol. 2011; 31(6):812-26. DOI: 10.1016/j.urolonc.2011.09.004. View

15.

Wu M, Li H, Yu L, Chen X, Kong Q, Song X . Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One. 2014; 9(2):e89806. PMC: 3934942. DOI: 10.1371/journal.pone.0089806. View

16.

Xue S, Xiao-Hong S, Lin S, Jie B, Li-Li W, Jia-Yao G . Lumbar puncture-administered resveratrol inhibits STAT3 activation, enhancing autophagy and apoptosis in orthotopic rat glioblastomas. Oncotarget. 2016; 7(46):75790-75799. PMC: 5342778. DOI: 10.18632/oncotarget.12414. View

17.

Klaassen C, Liu L, Dunn 2nd R . Regulation of sulfotransferase mRNA expression in male and female rats of various ages. Chem Biol Interact. 1998; 109(1-3):299-313. DOI: 10.1016/s0009-2797(97)00141-5. View

18.

Lindsay J, Wang L, Li Y, Zhou S . Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab. 2008; 9(2):99-105. DOI: 10.2174/138920008783571819. View

19.

Stocco B, Toledo K, Salvador M, Paulo M, Koyama N, Toloi M . Dose-dependent effect of resveratrol on bladder cancer cells: chemoprevention and oxidative stress. Maturitas. 2012; 72(1):72-8. DOI: 10.1016/j.maturitas.2012.02.004. View

20.

Patel K, Scott E, Brown V, Gescher A, Steward W, Brown K . Clinical trials of resveratrol. Ann N Y Acad Sci. 2011; 1215:161-9. DOI: 10.1111/j.1749-6632.2010.05853.x. View